Artículo de revista
A multi-institutional validation of the prognostic value of the Neutrophil-to-Lymphocyte ratio in patients with diffuse large B-cell lymphoma: A study from the Latin American Group of Q1 lymphoproliferative disorders (GELL)
Fecha
2020Registro en:
Clinical Lymphoma Myeloma & Leukemia Volumen: 20 Número: 10 Páginas: 637-646 Oct 2020
10.1016/j.clml.2020.04.016
Autor
Beltrán, Brady E.
Villela, Luis
Torres, María A.
Otero, Victoria
Fiad, Lorena
Peña, Camila
Cabrera, María E.
León, Pilar
Idrobo, Henry
Castro, Denisse A.
Paredes, Sally
Perdomo, Iván
Abello, Virginia
Rojas, Christine
Ramírez Ibarguen, Ana
Candelaria, Myrna
Pérez Jacobo, Fernando
Montano Figueroa, Efren
Best, Carlos
Gómez de León, Andrés
Gómez Almaguer, David
Ruiz Arguelles, Guillermo
Hernández Hernández, José
Malpica, Luis
Sotomayor, Eduardo M.
Castillo, Jorge J.
Institución
Resumen
International Prognostic Index and the National Comprehensive Cancer Network-International Prognostic Index score.
Introduction: We aimed at investigating the prognostic role of the neutrophil-to-lymphocyte ratio (NLR) in 2 independent cohorts of Latin American patients with diffuse large B-cell lymphoma (DLBCL) treated with chemo-immunotherapy. Patients and Methods: The learning cohort was composed of 274 patients and the validation cohort of 323 patients, for a total of 597 patients. An optimal NLR cutoff >= 4 was determined using receiver operating characteristic analysis. Results: In multivariate models, NLR >= 4 was independently associated with lower odds for complete response to chemoimmunotherapy in the learning (odds ratio, 0.46; P = .006) and the validation cohort (odds ratio, 0.49; P = .01), and independently associated with worse survival in the learning (hazard ratio, 1.55; P = .04) and the validation cohort (hazard ratio, 1.80; P = .003). Conclusions: The adverse prognostic value of NLR >= 4 was independent of the International Prognostic Index and the National Comprehensive Cancer Network-International Prognostic Index score. Based on the results of this multi-institutional study, NLR >= 4 emerges as an adverse prognostic factor in Latin American patients with DLBCL treated with chemoimmunotherapy.